RxDoctor Payments Data

Lindsay Miller, PA

Medical · Redding, CANPI 1235205931

Payments from drug & device makers

$13,955in general payments, 2019–2025

Across 489 payments — averaging $28.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$6K
  • Johnson & Johnson$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novartis$1K
  • LEO Pharma Inc.$429
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$4,85535%
  • Food & beverage$8,53461%
  • Education$5654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,955 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$167,336
Medicare patients
874
Services billed
2,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$349,881
Taltz AutoinjectorIxekizumab40$268,150
StelaraUstekinumab15$240,732
TremfyaGuselkumab11$150,818
AdbryTralokinumab-Ldrm40$121,767
Taltz SyringeIxekizumab14$97,010
Cosentyx Sensoready (2 Pens)Secukinumab12$87,060
Dupixent PenDupilumab22$82,110
OpzeluraRuxolitinib Phosphate26$52,422
Dupixent SyringeDupilumab11$41,658
Imiquimod20$5,647
Ivermectin26$5,423
Metronidazole47$2,041
Tretinoin21$1,669
Fluorouracil16$1,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya$1,640$391,55026 claims
LEO Pharma Inc.Adbry$429$121,76740 claims
Incyte CorporationOpzelura$393$52,42226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →